Latham & Watkins Advises on Oversubscribed US$150 Million Private Placement in Connection With Werewolf Therapeutics and Ambros Therapeutics’ Reverse Merger Transaction

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc. have announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (CRPS-1, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol AMBX.

In connection with the proposed merger, the companies secured commitments for an oversubscribed concurrent private placement of US$150 million from a syndicate of leading healthcare-dedicated investors.

Latham & Watkins LLP advised the placement agents in the transaction with a corporate team led by San Diego partner Matt Bush, with associates Omeed Valipour and Ariana Alemi.